Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15772MR)

This product GTTS-WQ15772MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ15772MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9976MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ14124MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ1084MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ6702MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ9967MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ3571MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ7173MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ4085MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI 836
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW